Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial

PLoS ONE
Q1
Jul 2015
Citations:24
Influential Citations:3
Interventional (Human) Studies
87
S2 IconPDF Icon

Enhanced Details

Methods
Double-blind, randomized, placebo-controlled two-stage trial in asymptomatic HIV-seropositive adults with CD4 >350 cells/μL, aged 21–64; enrolled from Edendale Hospital, KwaZulu-Natal; Stage 1 enrolled 56 participants and Stage 2 enrolled 77; final analysis included 107 participants (54 in S. frutescens 1,200 mg arm and 53 in placebo).
Intervention
Sutherlandia frutescens (dried leaf powder) capsules; 400 mg twice daily, 800 mg twice daily, or 1,200 mg twice daily for 24 weeks; Stage 2 used 1,200 mg twice daily versus placebo for 24 weeks.
Results
No change in HIV viral load or CD4 count at 24 weeks. Burden of infection (BOI) was higher in the S. frutescens arm (mean 9.0 days) vs placebo (5.0 days; p=0.045), driven by two tuberculosis cases in IPT. Safety parameters largely unchanged; two serious adverse events occurred in the S. frutescens arm (miscarriage and shingles) not attributed to the product. Conclusion: A possible interaction between S. frutescens and IPT requires further evaluation and may signal antagonistic interactions with other antioxidant herbs; no other major safety issues identified.
Limitations
Single-site KwaZulu-Natal study with a small, predominantly female sample; exclusion of ART users limits generalizability; infection-duration data partly retrospective; potential variability in plant preparation; possible interaction with IPT limiting applicability in settings where IPT is used.

Abstract

Background Sutherlandia frutescens (L.) R. Br. is widely used as an over the counter complementary medicine and in traditional medications by HIV seropositive adults living in South Africa; however the plant’s safety has not been objectively studied....